Synlogic, Inc. (NASDAQ:SYBX – Get Free Report)’s stock price crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.69 and traded as high as $0.7230. Synlogic shares last traded at $0.7110, with a volume of 70,770 shares.
Synlogic Stock Up 4.5%
The company has a market cap of $8.57 million, a P/E ratio of -2.82 and a beta of 0.54. The firm’s 50 day moving average is $0.69 and its two-hundred day moving average is $0.71.
Institutional Investors Weigh In On Synlogic
Several institutional investors and hedge funds have recently made changes to their positions in SYBX. DRW Securities LLC acquired a new position in shares of Synlogic in the fourth quarter worth approximately $27,000. Citadel Advisors LLC acquired a new stake in Synlogic during the 3rd quarter valued at approximately $49,000. Finally, Renaissance Technologies LLC increased its position in Synlogic by 116.7% during the 4th quarter. Renaissance Technologies LLC now owns 85,627 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 46,117 shares during the period. Institutional investors and hedge funds own 63.40% of the company’s stock.
About Synlogic
Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.
See Also
- Five stocks we like better than Synlogic
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.
